Please check your internet connection and try again.
# Sompraz HP (Pantoprazole)
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Healing of erosive esophagitis.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. A lower dose of 20 mg daily may be used for maintenance in some patients.
* **Symptomatic GERD (without erosive esophagitis):** 20 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Initially 40 mg orally twice daily. Doses may be increased as clinically warranted. Doses up to 240 mg daily have been administered (given as 40 mg three times daily).
## Pediatric Dosing
* **Erosive esophagitis (ages 5 to 16 years):** 20 mg or 40 mg orally once daily for up to 8 weeks. The choice between 20 mg and 40 mg should be based on the severity of esophagitis.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose is 20 mg orally once daily.
* **Renal Impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term PPI use may be associated with increased risk of fractures (hip, wrist, spine), Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Warfarin:** Monitor INR closely.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, digoxin, mycophenolate mofetil.
* **CYP2C19 substrates:** Clopidogrel (reduced efficacy).
## Monitoring
* Monitor for signs and symptoms of Clostridium difficile infection.
* Monitor serum magnesium levels periodically, especially with concomitant diuretic use or in patients receiving prolonged therapy.
* Monitor for signs of bone fracture in patients at risk.
* For patients on warfarin, monitor INR closely.
## Clinical Pearls
* Administer 30-60 minutes before a meal.
* Delayed-release formulations should not be crushed or chewed.
* Long-term use should be reserved for patients requiring pharmacotherapy for proven conditions.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for diagnosis and treatment.
